



Financial Results (Consolidated) for the the Fiscal Year ended March 31, 2019

FUJIFILM Holdings Corporation

Kenji Sukeno

President and Chief Operating Officer

Date of annual shareholders' meeting: June 27, 2019

Projected date of annual securities report: June 28, 2019

Reference materials regarding operating results of the current fiscal year to be prepared: Yes

Meeting to explain operating results of the current fiscal year to be held: Yes

(Consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.)

May 8, 2019

URL: <http://www.fujifilmholdings.com/>

Projected date of the beginning of cash dividends: June 28, 2019

1. Results of the Fiscal Year ended March 31, 2019 (From April 1, 2018 to March 31, 2019)

(1) OPERATING RESULTS

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen
%: Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Income before income taxes		Net income attributable to FUJIFILM Holdings	
		%		%		%		%
Year ended March 31, 2019	2,431,489	(0.1)	209,827	70.1	212,762	7.6	138,106	(1.8)
Year ended March 31, 2018	2,433,365	4.8	123,329	(25.9)	197,807	1.6	140,694	7.0

Note: Comprehensive income

Year ended March 31, 2019 ¥ 164,517 million (50.2%)

Year ended March 31, 2018 ¥ 109,533 million ((11.1)%)

	Net income attributable to FUJIFILM Holdings per share	Net income attributable to FUJIFILM Holdings per share (Assuming full dilution)	Return on FUJIFILM Holdings shareholders' equity	Ratio of income before income taxes to total assets	Ratio of operating income to revenue
	Yen	Yen	%	%	%
Year ended March 31, 2019	326.81	325.82	6.7	6.2	8.6
Year ended March 31, 2018	322.62	321.55	6.8	5.6	5.1

(Ref) Equity in net earnings of affiliated companies

Year ended March 31, 2019 ¥ 418 million

Year ended March 31, 2018 ¥ 872 million

(2) FINANCIAL POSITION

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

	Total assets	Total equity (Net asset)	FUJIFILM Holdings shareholders' equity	FUJIFILM Holdings shareholders' equity ratio to total assets	FUJIFILM Holdings shareholders' equity per share
				%	Yen
Year ended March 31, 2019	3,414,692	2,244,841	2,036,963	59.7	4,976.88
Year ended March 31, 2018	3,492,940	2,298,706	2,079,134	59.5	4,832.62

(3) CASH FLOWS

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

	Net Cash provided by Operating Activities	Net Cash used in Investing Activities	Net Cash used in Financing Activities	Cash and Cash Equivalents at the end of year
Year ended March 31, 2019	249,343	(208,585)	(153,522)	654,747
Year ended March 31, 2018	261,152	(111,786)	(258,961)	768,246

2. Cash Dividends

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

	Cash dividends per share					Total cash dividends	Consolidated pay out ratio	Ratio of cash dividends to shareholders' equity
	1st Quarter	2nd Quarter	3rd Quarter	Year End	Year Total			
	Yen	Yen	Yen	Yen	Yen		%	%
Year ended March 31, 2018	-	37.50	-	37.50	75.00	32,526	23.2	1.6
Year ended March 31, 2019	-	40.00	-	40.00	80.00	33,403	24.5	1.6
Year ending March 31, 2020 (Forecast)	-	47.50	-	47.50	95.00		25.1	

3. Forecast for the Fiscal Year ending March 31, 2020 (From April 1, 2019 to March 31, 2020)

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

%: Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Income before income taxes		Net income attributable to FUJIFILM Holdings		Net income attributable to FUJIFILM Holdings per share
		%		%		%		%	Yen
For the Year ending March 31, 2020	2,480,000	2.0	240,000	14.4	245,000	15.2	155,000	12.2	378.71

Note: Net income attributable to FUJIFILM Holdings per share is calculated using the number of shares issued as of March 31, 2019 excluding treasury shares for the average number of shares for the relevant period.

Notes

(1) Changes in status of material subsidiaries during the period

(Company newly consolidated or removed from consolidation): None

(2) Changes in accounting principles

1. Changes in accounting policies accompanying amendment of accounting standards: Yes

2. Other changes in accounting policies: None

(3) Number of shares outstanding

1. Issued (including treasury stock):

2. Treasury stock:

3. Average number of shares:

As of March 31, 2019	514,625,728	As of March 31, 2018	514,625,728
As of March 31, 2019	105,340,377	As of March 31, 2018	84,396,402
Year ended March 31, 2019	422,591,209	Year ended March 31, 2018	436,097,994

(Reference) Summary of Financial Results (Non-Consolidated)

Results of the Fiscal Year ended March 31, 2019 (From April 1, 2018 to March 31, 2019)

(1) OPERATING RESULTS

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded down to the nearest million yen

%: Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Ordinary income		Net income	
		%		%		%		%
Year ended March 31, 2019	72,382	56.3	66,892	62.0	64,974	(6.6)	65,240	4.7
Year ended March 31, 2018	46,321	56.2	41,300	61.1	69,535	77.9	62,308	83.1

	Net income per share of common stock	Net income per share of common stock (Assuming full dilution)
	Yen	Yen
Year ended March 31, 2019	154.38	153.90
Year ended March 31, 2018	142.88	142.43

(2) FINANCIAL POSITION

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded down to the nearest million yen

	Total assets	Net assets	Net asset ratio to total assets	Net assets per share of common stock
			%	Yen
Year ended March 31, 2019	1,707,924	1,091,421	63.7	2,656.98
Year ended March 31, 2018	1,861,275	1,372,846	73.5	3,181.40

(Ref) Shareholders' equity

Year ended March 31, 2019 ¥ 1,087,463 million

Year ended March 31, 2018 ¥ 1,368,731 million

Disclosure regarding the status of the year-end audit process

These Financial Results (Consolidated) for the Fiscal Year ended March 31, 2019 are out of scope for the year-end audit procedure by certified public accountants or audit firm.

Explanation of Appropriate Use of Forecast and Other Special Items

Statements regarding future events including forecasts of operating results are based on limited available information and reasonable assumptions as of today. The Company does not have the intention of guaranteeing the realization of future performance. Actual operating results are always subject to change significantly due to various matters.

Assumptions for the forecast and warnings for users of the forecast are mentioned in the page 5, Outlook for the Fiscal Year ending March 31, 2020 of the section (1) Analysis of Results of Operations in 1. ANALYSIS OF OPERATING RESULTS AND CONSOLIDATED FINANCIAL POSITION.

[INDEX]

1.	ANALYSIS OF OPERATING RESULTS AND CONSOLIDATED FINANCIAL POSITION		
(1)	Analysis of Results of Operations	• • • • •	P. 2
(2)	Analysis of Consolidated Financial Position	• • • • •	P. 5
(3)	Basic Policy Regarding Distribution of Profits and Dividends Applicable to the Fiscal Year under Review and Subsequent Fiscal Year	• • • • •	P. 6
2.	CORPORATE STRUCTURE OF FUJIFILM GROUP	• • • • •	P. 6
3.	MANAGEMENT POLICIES	• • • • •	P. 7
4.	BASIC RATIONALE FOR SELECTION OF ACCOUNTING STANDARDS	• • • • •	P. 8
5.	CONSOLIDATED FINANCIAL STATEMENTS		
(1)	Consolidated Balance Sheets	• • • • •	P.9
(2)	Consolidated Statements of Income and Consolidated Statements of Comprehensive Income	• • • • •	P.11
	(Consolidated Statements of Income)	• • • • •	P.11
	Year ended March 31	• • • • •	P.11
	Three months ended March 31	• • • • •	P.12
	(Consolidated Statements of Comprehensive Income)	• • • • •	P.13
	Year ended March 31	• • • • •	P.13
	Three months ended March 31	• • • • •	P.13
(3)	Consolidated Statements of Changes in Shareholders' Equity	• • • • •	P.14
(4)	Consolidated Statements of Cash Flows	• • • • •	P.15
(5)	Notes to Consolidated Financial Statements	• • • • •	P.16
	(Note Relating to the Going Concern Assumption)	• • • • •	P.16
	(Summary of Significant Accounting Policies)	• • • • •	P.16
	(Segment Information)	• • • • •	P.17
	1) Year ended March 31	• • • • •	P.17
	2) Three months ended March 31	• • • • •	P.21
	(Amounts Per Share of Common Stock)	• • • • •	P.22
	(Subsequent Event)	• • • • •	P.22

1. ANALYSIS OF OPERATING RESULTS AND CONSOLIDATED FINANCIAL POSITION

(1) Analysis of Results of Operations

Amount Unit: Billions of yen

	Year ended March 31, 2019 From April 1, 2018 To March 31, 2019		Year ended March 31, 2018 From April 1, 2017 To March 31, 2018		Change	
					Amount	%
Domestic revenue	41.4%	1,006.5	41.4%	1,006.5	0.0	0.0
Overseas revenue	58.6%	1,425.0	58.6%	1,426.9	(1.9)	(0.1)
Revenue	100.0%	2,431.5	100.0%	2,433.4	(1.9)	(0.1)
Operating income	8.6%	209.8	5.1%	123.3	86.5	70.1
Income before income taxes	8.8%	212.8	8.1%	197.8	15.0	7.6
Net income attributable to FUJIFILM Holdings	5.7%	138.1	5.8%	140.7	(2.6)	(1.8)
Exchange rates (Yen / US\$)		¥111		¥111		¥0
Exchange rates (Yen / Euro)		¥128		¥130		(¥2)

Overviewing the global economy during the fiscal year ended March 31, 2019 (April 1, 2018 through March 31, 2019), the general trend of gradual economic recovery persisted despite some weakness observed in China and a part of Europe. In the U.S., the trend of economic recovery persisted steadily through increase in personal consumption and capital investments. In Europe, the trend of gradual economic recovery maintained although it has weakened in some areas. In China, the economy gradually slowed reflecting lower growth in consumption. Other Asian regions showed gradual economic recovery despite the trend has weakened in some areas. In Japan, the general trend of gradual economic recovery persisted with personal consumption picking up due to the improvement in the employment and income environment.

In the fiscal year ended March 31, 2019, the Group recorded ¥2,431.5 billion in consolidated revenue (down 0.1% from the previous fiscal year), reflecting such factors as a sales decrease in the document business, although sales increased in the medical systems business, bio CDMO business, regenerative medicine business and electronic materials business.

Operating income largely increased to ¥209.8 billion (up 70.1% from the previous fiscal year) due to improved profitability and positive impacts of structural reforms in the document business. Consolidated income before income taxes amounted to ¥212.8 billion (up 7.6% from the previous fiscal year) and consolidated net income attributable to FUJIFILM Holdings totaled ¥138.1 billion (down 1.8% from the previous fiscal year). The effective currency exchange rates for the U.S. dollar and the euro against the yen during this fiscal year were ¥111 and ¥128, respectively.

Revenue by Operating Segment

Amount Unit: Billions of yen

Segment	Year ended March 31, 2019 From April 1, 2018 To March 31, 2019		Year ended March 31, 2018 From April 1, 2017 To March 31, 2018		Change	
					Amount	%
Imaging Solutions		386.9		383.0	3.9	1.0
Healthcare & Material Solutions		1,039.0		1,002.6	36.4	3.6
Document Solutions		1,005.6		1,047.8	(42.2)	(4.0)
Consolidated Total		2,431.5		2,433.4	(1.9)	(0.1)

Operating Income by Operating Segment

Amount Unit: Billions of yen

Segment	Year ended March 31, 2019 From April 1, 2018 To March 31, 2019	Year ended March 31, 2018 From April 1, 2017 To March 31, 2018	Change	
			Amount	%
Imaging Solutions	51.1	55.8	(4.7)	(8.4)
Healthcare & Material Solutions	97.6	91.4	6.2	6.8
Document Solutions	96.4	8.4	88.0	1,045.3
Corporate Expenses and Eliminations	(35.3)	(32.3)	(3.0)	-
Consolidated Total	209.8	123.3	86.5	70.1

Imaging Solutions

In the Imaging Solutions segment, consolidated revenue amounted to ¥386.9 billion (up 1.0% from the previous fiscal year), due to a solid sales increase in all businesses.

Consolidated operating income amounted to ¥51.1 billion (down 8.4% from the previous fiscal year), due to such factors as advertising and promotion costs and R&D investments.

In the photo imaging business, revenue increased due to favorable sales, mainly in instant photo systems that enable users to enjoy on-the-spot printing of photos, such as the *instax* series and *instax* films. The global promotions featuring Taylor Swift as *instax*'s global partner contributed to strong sales of instant photo systems worldwide, especially in Europe and the U.S. In the high-value-added printing business, sales were strong for *Wall Decor* services that enable users to enjoy decorating their walls by displaying photos as stylish interior. In addition, the *FUJIFILM PhotoBank*, a cloud-based photo service, was announced to start this spring. The service offers a new lifestyle utilizing photos, enabling users to not only share photos and order printing, but also purchase goods that suit their interests, suggested by AI according to users' preferences based on the photos saved.

In the electronic imaging field of the optical device and electronic imaging business, sales were strong for *FUJIFILM X-T3*, which has high-speed, high-precision auto focus function and high video function, and *FUJIFILM X-T30*, which has a small and light body with high performances, launched in March 2019. *FUJIFILM GFX 50R*, a medium format mirrorless digital camera, showed strong sales reflecting good reviews on its ultrahigh image quality incorporating a large sensor and its adoption of range finder style. As a result, overall revenue of mirrorless digital cameras increased from the previous fiscal year despite the downward trend in the digital camera market in the fiscal year 2018. The sales of interchangeable lenses also increased accordingly.

In the optical device field, sales increased steadily mainly for various industrial use lenses including vehicle-mounted lenses. In February 2019, Fujifilm announced its entry into the projection equipment market with *FUJIFILM PROJECTOR Z5000*, combining optical technologies of *FUJINON Lenses*. Fujifilm expands its business field and aims for further business growth.

Healthcare & Material Solutions

In the Healthcare & Material Solutions segment, consolidated revenue amounted to ¥1,039.0 billion (up 3.6% from the previous fiscal year) due to strong sales in the medical systems business, bio CDMO business, regenerative medicine business, electronic materials business and others.

Operating income amounted to ¥97.6 billion (up 6.8% from the previous fiscal year), mainly due to an improvement of profitability.

In the medical systems business, revenue increased due to strong sales in all business fields such as X-ray imaging diagnostics, medical IT, endoscopes, ultrasound diagnostics and In-vitro Diagnostics fields (IVD). In the X-ray imaging diagnostics field, the sales of *CALNEO Xair*, a portable X-ray imaging device with a light and small body that supports simple X-ray examinations in limited space, started in Japan from October 2018. The sales of DR equipment including this new product showed favorable growth and increased revenue. In the medical IT field, sales of systems, particularly *SYNAPSE*, the Picture Archiving Communication Systems

(PACS), were strong especially in Japan and the U.S. In the endoscopes field, strong sales were seen for such products as the 7000 systems capable of special-light illumination. In the ultrasound diagnostics field, sales were strong for products such as the full-flat *SonoSite S II* and the portable *SonoSite Edge II*, in major markets such as the U.S., Europe, Japan and China. In the IVD field, the sales of the *DRI-CHEM* series, a densitometry analysis system, were strong mainly in overseas market.

In the pharmaceutical business, revenue decreased mainly due to an influence of generic drugs in the small-molecular drugs. In September 2018, Fujifilm Kyowa Kirin Biologics Co., Ltd., Fujifilm's affiliated company, obtained marketing authorization from the European Commission for Hulio®, a biosimilar to *adalimumab*, a human monoclonal antibody against TNF-alpha. Its sales in Europe started through Mylan, a sales partner. In January 2019, Fujifilm also launched *PROOFIT ID*, a pouch verification system that supports pharmacists in their verification operations at pharmacies by automatically identifying the name and quantity of medication pouched. Also in March 2019, Fujifilm started clinical trials with National Cancer Center Japan for new immunotherapy of cancer utilizing its liposome, a drug delivery system technology. Fujifilm continues its contribution in solving social issues through development and provision of innovative and high value-added medicines.

In the bio CDMO business, the sales in the contract process development and manufacturing business for biopharmaceuticals progressed steadily. In March 2019, Fujifilm announced the acquisition of Biogen (Denmark) Manufacturing ApS, a manufacturing subsidiary of Biogen Inc., a U.S. based large biopharmaceutical company, to further expand its businesses by accelerating the growth of contract process development and manufacturing business for biopharmaceuticals.

In the regenerative medicine business, revenue increased due to favorable sales of cell culture media for biopharmaceuticals by Irvine Scientific Sales Company, Inc. (currently FUJIFILM Irvine Scientific), a leading company in cell culture media. Furthermore, FUJIFILM Cellular Dynamics, a subsidiary in the U.S., launched *iCell® Microglia*, an iPSC-derived cell type that enables an evaluation of new medicines for degenerative neurological diseases such as Alzheimer's disease in a similar environment to the human body. Fujifilm will contribute to early industrialization of regenerative medicine by utilizing technologies and know-how of its group companies.

In the life sciences business, the sales of new products started in March 2019, including *ASTALIFT D-UV CLEAR WHITE SOLUTION* with the highest UV-protection effect, and a revamped *ASTALIFT WHITE ESSENCE INFILT* with enhanced beauty effect. The sales of supplements such as the *MetabARRIER* series showed steady growth, resulting in increased revenue.

In the display materials business, revenue increased due to solid sales of TAC products and products related to OLED and touch-panels.

In the industrial products business, sales were strong for *EXCLEAR*, touch-panel sensor film, along with solid sales of *Prescale*, pressure measurement film.

Revenue in the electronic materials business increased, reflecting strong sales of such products as advanced peripheral materials related to photolithography, CMP slurries, Image Sensor Color Mosaic, polyimide for advanced package and others.

In the fine chemical business, revenue remained on the same level as the previous year with the solid sales of laboratory chemicals for research institutes and contract services for inspections and analysis in the life science field.

In the recording media business, revenue decreased due to the inventory adjustment of magnetic tape for high volume data storage and other factors. Fujifilm is expanding the sales of magnetic tape for data storage, which uses barium ferrite (BaFe) particles and also providing a data archive service etc. to certainly meet customer's need in this big data era.

In the graphic systems business, revenue decreased mainly due to a decline in total demand of graphic arts film and CTP plates. In March 2019, Fujifilm launched the *Jet Press750S*, as a new lineup of the *Jet Press* series of commercial inkjet digital press. Fujifilm continues to develop and provide innovative products to the rapidly digitalized commercial printing market for business expansion.

In the inkjet business, revenue decreased due to such factors as the inventory adjustment of industrial inkjet printheads by customers. Fujifilm plans to expand its business not only in the existing commercial printing and display field, but also in new areas such as textile and packaging by providing unique products.

Document Solutions

In the Document Solutions segment, consolidated revenue amounted to ¥1,005.6 billion (down 4.0% from the previous fiscal year) due to such factors as a reduction in low-profitability parts of the low-end office printer business.

Operating income amounted to ¥96.4 billion (up 1,045.3% from the previous fiscal year) due to improved profitability, a positive impact from structural reforms and so on.

Regarding the office products field of the office products and printers business, overall sales volume decreased from the previous fiscal year, although the sales were solid for the *ApeosPort-VII C / DocuCentre-VII C* series consisting of color multifunction devices with enhanced security functions added in December 2018. In the office printer field, sales volume decreased due to a reduction in low-profitability parts of low-end printers business.

In the production services business, though the overall number of sales unit fell from the same period of the previous fiscal year, strong sales remained for an on-demand production color printer called the *Iridesse™ Production Press* especially in Europe and the U.S. In January 2019, Fuji Xerox announced the launch of the *11000 Inkjet Press*, a high-speed roll color inkjet printer for commercial printing with image quality comparable to that of offset printing. Its sales started from February 2019 in Japan, with an aim for further growth by expanding the digitalization of commercial printing.

In the solutions and services business, overall revenue increased due to new contracts for BPO (Business Process Outsourcing) and solid sales of business-specific solutions. In February 2019, Fuji Xerox began offering a cloud-based accounts payable management system under partnership with Esker (France). The system significantly reduces cumbersome operations of processing bills by automatic extraction of billing data that differ per supplier utilizing AI (artificial intelligence). We aim further growth in the service field by continuously providing services that support customers in diversification of work styles under the new value creation strategy called *Smart Work Innovation*.

Outlook for the Fiscal Year ending March 31, 2020

Amount Unit: Billions of yen

	Year ending March 31, 2020 (Forecast)	Year ended March 31, 2019 (Actual)	Change (%)
Revenue	2,480.0	2,431.5	2.0
Operating income	240.0	209.8	14.4
Income before income taxes	245.0	212.8	15.2
Net income attributable to FUJIFILM Holdings	155.0	138.1	12.2
ROE (%)	7.5	6.7	+0.8pt
Exchange rates			
(Yen / US \$)	¥ 110	¥ 111	(¥ 1)
(Yen / Euro)	¥ 125	¥ 128	(¥ 3)

Regarding consolidated performance in the fiscal year ending March 31, 2020, through accelerating growth of the healthcare and highly functional materials business fields, which are core business fields of the Group, fundamental reinforcement of the document business, and improvement of profitability in each business, the Company projects ¥2,480.0 billion in revenue (up 2.0% from the previous fiscal year), operating income of ¥240.0 billion (up 14.4% from the previous fiscal year), income before income taxes of ¥245.0 billion (up 15.2% from the previous fiscal year), and net income attributable to FUJIFILM Holdings of ¥155.0 billion (up 12.2% from the previous fiscal year). In the Document Solutions segment, ¥10.0 billion as one-time costs for structural reforms and other factors, and ¥18.0 billion as positive impacts from structural reforms, are expected.

The projected currency exchange rates for the U.S. dollar and the euro against the yen during the fiscal year

ending March 31, 2020 are ¥110 and ¥125, respectively.

(2) Analysis of Consolidated Financial Position

(Assets, Liabilities, Shareholders' Equity, and Cash Flows)

At the end of the fiscal year ended March 31, 2019, total assets decreased by ¥78.2 billion, compared with the end of the previous fiscal year, to ¥3,414.7 billion, owing to decrease in cash and cash equivalents and other factors. Total liabilities decreased by ¥24.4 billion, compared with the end of the previous fiscal year, to ¥1,169.9 billion. FUJIFILM Holdings shareholders' equity decreased by ¥42.2 billion, compared with the end of the previous fiscal year, to ¥2,037.0 billion. As a result, the current ratio decreased by 33.6 percentage points, to 246.5%, the debt-equity ratio decreased by 0.0 percentage points, to 57.4%, and the equity ratio increased by 0.2 percentage points, to 59.7%, compared with the end of the previous fiscal year. The Company is maintaining a stable level of asset liquidity and a sound capital structure.

During the fiscal year ended March 31, 2019, net cash provided by operating activities totaled ¥249.3 billion, due to a decrease in notes and accounts receivable and other factors. Net cash used in investing activities amounted to ¥208.6 billion, mainly due to acquisition of businesses. Thus, free cash flows—or the sum of cash flows from operating and investing activities—decreased by ¥108.6 billion, compared with the previous fiscal year, to ¥40.8 billion. Net cash used in financing activities amounted to ¥153.5 billion, due to net purchases of stock for treasury, capital transactions with noncontrolling interests and other factors.

As a result, cash and cash equivalents at the end of the fiscal year under review amounted to ¥654.7 billion, down ¥113.5 billion from the end of the previous fiscal year.

(Reference) Cash Flow Related Indices (Consolidated)

	Year ended March 31, 2019 From April 1, 2018 To March 31, 2019	Year ended March 31, 2018 From April 1, 2017 To March 31, 2018
Ratio of shareholders' equity to total assets (%)	59.7	59.5
Ratio of market capitalization to total assets (%)	60.3	52.3
Ratio of interest-bearing debt to operating cash flow (years)	2.1	1.7
Interest coverage ratio (times)	75.2	57.1

Notes:

1. Market capitalization equals the stock price at the end of the year multiplied by the number of shares outstanding at the end of the fiscal year, excluding treasury stock.
2. Interest-bearing debt includes corporate debt securities and short- and long-term debt.
3. Interest coverage ratio: Operating cash flow divided by interest paid

(3) Basic Policy Regarding Distribution of Profits and Dividends Applicable to the Fiscal Year under Review and Subsequent Fiscal Year

In addition to reflecting consolidated performance trends, dividend levels are to be determined based on the consideration of such factors as the level of funds required for M&A transactions, capital investment and new product development investments needed to support priority business expansion, as well as other measures aimed at increasing the Company's corporate value in the future. Adequate buybacks will be undertaken considering the situation of cash flows and stock prices. The Company has the policy of shareholder returns that puts emphasis on cash dividends, setting the targeted dividend payout ratio of 25% or more.

The Company plans to disburse year-end cash dividends of ¥40.00 per share. As interim cash dividends of ¥40.00 per share have already been disbursed, cash dividends applicable to the fiscal year under review are expected to total ¥80.00 per share.

Regarding the fiscal year ending March 31, 2020, the Company anticipates that interim dividends, year-end dividends and total dividends applicable to the year will be ¥47.50, ¥47.50, and ¥95.00 per share, respectively.

2. CORPORATE STRUCTURE OF FUJIFILM GROUP

Since there have not been any significant changes in business and group structures disclosed in the latest Annual Security Report filed on June 29, 2018, we omit the relevant disclosure.

3. MANAGEMENT POLICIES

After the year 2000, when the demand for photographic films started to decline sharply and rapidly, the Group proceeded with a conversion of its business structure with speed and confidence. As a result, the Group has built a strong management base to generate stable profit and cash to enter into a new growth phase. In August 2017, the new CSR program for the fiscal year ending March 31, 2031, called “Sustainable Value Plan 2030 (hereafter “SVP2030”),” was drawn up, aiming to resolve social issues through our business activities, such as delivery of innovative technologies, goods and services, to establish the Group as a contributor in building sustainable society. The medium-term management plan “VISION2019” was also compiled as a specific action plan for achieving the vision set out in the SVP2030. The Group set each of businesses as the stages of “improving profitability,” “accelerating growth” and “investing for the future.” By further strengthening profitability in each business by appropriate developing plans adjusted each situation, the Group is consolidating its business portfolio to achieve a further leap forward.

Uncertainties and unclear outlook are set to continue in the fiscal year ending March 31, 2020, amidst trade friction between the U.S. and China, Brexit and immigration issues in Europe, trends surrounding China and other emerging economies, geopolitical risks in North Korea and Syria, and last-minute demand before the consumption tax raise and its backlash in Japan. The Group strives to further boost profitability of its business operations to generate stable cash-flow, with particular emphasis on “accelerating growth of healthcare and highly functional materials business fields” and “fundamental reinforcement of document business,” thereby consolidating our business portfolio.

[Accelerating business growth in healthcare and highly functional materials business fields]

In the healthcare business field, the medical systems business and bio CDMO business will drive sales growth to ensure increase in income and profit. The pharmaceutical business and regenerative medicine business will be fostered by accelerating R&D while controlling profits and losses.

The medical systems business takes advantage of its broad product lineup based on image processing technology, ranging from X-ray diagnostic imaging devices, medical IT systems, endoscopes, ultrasound and In-vitro Diagnostics (IVD), to revamp the delivery of comprehensive solutions built around its highly competitive medical IT. In medical IT, Fujifilm is pushing forward with development of AI-powered imaging diagnostic support systems. In addition to internal technology development, Fujifilm is building partnership with domestic and international AI vendors with superior technology and proceeding with speedy development in order to support doctors in image diagnostics and improve workflow efficiency by providing solutions that meet various needs at the medical front.

In the biopharmaceutical process development and contract manufacturing business, which is expected to see strong market growth, Fujifilm announced the acquisition of Biogen (Denmark) Manufacturing ApS in March 2019. At the U.S. sites of FUJIFILM Diosynth Biotechnologies, capital investment totaling ¥10.0 billion in two years is underway since January 2019. Production capacity is further expanded through capital investment and technological development to attain scale merit in boosting profitability and accelerating business growth.

In the pharmaceutical business, Fujifilm promotes efficient R&D for drug candidates such as the anti-cancer drug *FF-10501* and Alzheimer’s disease drug *T-817MA* to target areas of strong unmet medical needs. In the category of drug delivery systems that enables delivering drugs to required locations at pinpoint accuracy, Fujifilm is promoting its efforts to achieve commercial application of formulation technology based on proprietary technologies such as microneedles and liposomes.

In the regenerative medicine business, Fujifilm consolidated Irvine Scientific Sales Company, Inc. (currently FUJIFILM Irvine Scientific), a leading company in cell culture media, in June 2018, further consolidating the Group’s capability to develop “cells,” “culture media” and “scaffolds,” three key elements of regenerative medicine. While accelerating R&D in regenerative medicine and further expanding the contract development and manufacturing business for biopharmaceuticals to maximize synergy, Fujifilm is reinforcing collaboration with the public and academic sectors to contribute to the commercialization of regenerative medicine.

In each of the businesses in the highly functional materials business field, Fujifilm strives to maintain the current competitive edge and tap into its distinctive technological capability to achieve timely introduction of highly profitable products that meet market needs, thereby boosting both sales and income.

The growth of the electronic materials business will be accelerated by boosting the sales of existing products, such as advanced peripheral materials related to photolithography, and expanding the product lineup. Increasing use of AI, IoT, and next-generation communication standard “5G” and the advancement of autonomous driving technology are expected to bring further demand increase and performance boost for semiconductors. Given the situation, Fujifilm decided to make investments for ¥10.0 billion over three years starting in December 2018 to support further demand increase.

In the display materials business, Fujifilm is determined to maintain its market position for existing products, while tapping into thin-film and multilayer-coating technologies to expand the sales of new materials for

OLED, touch-panels and in-vehicle displays.

In the industrial product business, Fujifilm will expand the sales of high-function products, based on proprietary technologies, for innovative applications, such as the touch-panel sensor film, *EXCLEAR*, and the micro filters with an advanced level of microporous structure and filtering performance. The business is also boosted through a deployment of the cloud service that detects cracks on bridges and tunnels and turns the detection results into data, using AI-powered image analysis.

[Fundamental reinforcement of document business]

Under the concept of *Smart Work Innovation*, Fuji Xerox will encourage growth in the business by providing new solutions and services that support diversifying work styles, utilizing its unique AI, IoT and IoH technologies. At the same time, by carrying through the improvement of productivity utilizing RPA, and the structural reforms executed since the fiscal year ended March 2018, Fuji Xerox will improve earnings and productivity and transform into a lean company, thereby rendering the future development of the document business solid and secure.

In the office products and printers business, Fuji Xerox aims for revenue growth through expanded sales channels and further increase in its market share in Asia Oceania region including Japan and China, centering on the new *ApeosPort/DocuCentre* series of color multifunctional printers with strengthened security functions. Moreover, Fuji Xerox will ensure high profitability by providing cost-competitive products through shortened product development period.

In the production services business, Fuji Xerox will leverage our robust customer base and add value for users by turning the entire printing workflow into a service while also enhancing printing applications. Fuji Xerox also operate globally in the area of inkjet printing, making use of Fujifilm, Fuji Xerox, and Xerox Corporation's networks to achieve growth in the production service business.

In the solutions and services business, Fuji Xerox will improve profitability and accelerate business growth region-wide by actively making investments to increase business in growth area and expanding strategic partnership with cloud services that are highly valued in the market.

The Company positions corporate governance as an important management priority and focuses on its enhancement. In June 2018, the Company appointed Ms. Makiko Eda, who has ample experiences in corporate management and international business, as an independent director, further diversifying the structure of the Board of Directors and increasing the ratio of independent directors to 40%. At the same time, a voluntary Nomination and Remuneration Advisory Committee chaired by an independent director was established to discuss a succession plan of the CEO and a basic policy and procedures related to compensation for directors, enhancing transparency of the processes. Furthermore, intensive measures have been taken for strengthening management of group companies, such as the development of an IT environment capable of monitoring subsidiaries' management status, the execution of audit on all subsidiaries by the Company's audit division and the introduction of the internal whistleblowing system to allow the Group's all directors and employees to directly file a report with the Company's compliance management department. The Company will continue the enhancement of its corporate governance, compliance and risk management.

The Group adopted the basic policy for fiscal year ending March 31, 2020, as "Create Change! - Create Innovative Value for Society -". The fiscal year ending March 31, 2020 is the final year of the current medium-term plan "VISION2019"; it is also the year to sum up "VISION2019" and plant seeds for the next medium-term management plan. The Company will work on profitability-boosting initiatives across all business areas and introduction of products and services that bring innovative value to society by tackling business challenges with "strong determination and ownership" and "carrying out tasks to the very end", while strengthening actions based on a medium- and long-term perspective with "clear insight and out-of-the-box thinking".

4. BASIC RATIONALE FOR SELECTION OF ACCOUNTING STANDARDS

Due to the agreement related to the Eurodollar convertible bond issuance in 1970, the Group has prepared and disclosed its consolidated financial statements in accordance with accounting principles generally accepted in the United States of America.

The Company is considering the adaptation of IFRS through addressing internal and external factors that affect both within and outside of Japan.

5. CONSOLIDATED FINANCIAL STATEMENTS

FUJIFILM Holdings Corporation (4901)

(1) Consolidated Balance Sheets

Amount Unit: Millions of yen

	As of March 31, 2019	As of March 31, 2018	Change
ASSETS			
Current assets:			
Cash and cash equivalents	654,747	768,246	(113,499)
Notes and accounts receivable:			
Trade and finance	639,280	634,851	4,429
Affiliated companies	5,634	15,010	(9,376)
Allowance for doubtful receivables	(27,119)	(30,811)	3,692
	617,795	619,050	(1,255)
Inventories	374,456	361,321	13,135
Prepaid expenses and other	83,908	112,185	(28,277)
Total current assets	1,730,906	1,860,802	(129,896)
Investments and long-term receivables:			
Investments in and advances to affiliated companies	33,445	33,269	176
Investment securities	105,678	87,180	18,498
Long-term finance and other receivables	104,323	122,219	(17,896)
Allowance for doubtful receivables	(3,754)	(3,512)	(242)
Total investments and long-term receivables	239,692	239,156	536
Property, plant and equipment:			
Land	98,211	99,108	(897)
Buildings	690,207	720,853	(30,646)
Machinery and equipment	1,447,115	1,644,568	(197,453)
Construction in progress	36,420	28,863	7,557
	2,271,953	2,493,392	(221,439)
Less accumulated depreciation	(1,745,156)	(1,955,847)	210,691
Total property, plant and equipment	526,797	537,545	(10,748)
Other assets:			
Goodwill, net	655,508	591,568	63,940
Other intangible assets, net	145,013	127,137	17,876
Deferred income taxes	32,762	48,647	(15,885)
Other	84,014	88,085	(4,071)
Total other assets	917,297	855,437	61,860
Total assets	3,414,692	3,492,940	(78,248)

	As of March 31, 2019	As of March 31, 2018	Change
LIABILITIES			
Current liabilities:			
Short-term debt	170,579	41,676	128,903
Notes and accounts payable:			
Trade	210,658	224,012	(13,354)
Construction	25,758	21,169	4,589
Affiliated companies	1,940	3,367	(1,427)
	238,356	248,548	(10,192)
Accrued income taxes	18,950	28,226	(9,276)
Accrued liabilities	182,833	219,723	(36,890)
Other current liabilities	91,567	126,044	(34,477)
Total current liabilities	702,285	664,217	38,068
Long-term liabilities:			
Long-term debt	353,533	412,502	(58,969)
Accrued pension and severance costs	40,335	45,193	(4,858)
Deferred income taxes	19,959	17,298	2,661
Other long-term liabilities	53,739	55,024	(1,285)
Total long-term liabilities	467,566	530,017	(62,451)
Total liabilities	1,169,851	1,194,234	(24,383)
EQUITY			
FUJIFILM Holdings shareholders' equity			
Capital	40,363	40,363	-
Common stock, without par value:			
Authorized: 800,000,000 shares			
Issued: 514,625,728 shares			
Additional paid-in capital	24,494	79,153	(54,659)
Retained earnings	2,507,719	2,383,793	123,926
Accumulated other comprehensive income (loss)	(100,593)	(87,783)	(12,810)
Treasury stock, at cost			
As of March 31, 2018: 84,396,402 shares			
As of March 31, 2019: 105,340,377 shares	(435,020)	(336,392)	(98,628)
Total FUJIFILM Holdings shareholders' equity	2,036,963	2,079,134	(42,171)
Noncontrolling interests	207,878	219,572	(11,694)
Total equity	2,244,841	2,298,706	(53,865)
Total liabilities and equity	3,414,692	3,492,940	(78,248)

Note: Details of accumulated other comprehensive income (loss)

	As of March 31, 2019	As of March 31, 2018	Change
Unrealized gains (losses) on securities	(2)	18,976	(18,978)
Foreign currency translation adjustments	2,112	(3,786)	5,898
Pension liability adjustments	(102,463)	(102,524)	61
Unrealized gains (losses) on derivatives	(240)	(449)	209

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income
(Consolidated Statements of Income)

Year ended March 31

Amount Unit: Millions of yen

	Year ended March 31, 2019 From April 1, 2018 To March 31, 2019		Year ended March 31, 2018 From April 1, 2017 To March 31, 2018		Change	
					Amount	%
	%		%			
Revenue:	100.0	2,431,489	100.0	2,433,365	(1,876)	(0.1)
Cost of sales:	59.0	1,433,973	60.2	1,464,269	(30,296)	(2.1)
Gross profit	41.0	997,516	39.8	969,096	28,420	2.9
Operating expenses:						
Selling, general and administrative	26.0	631,557	27.8	677,827	(46,270)	(6.8)
Research and development	6.4	156,132	6.9	167,940	(11,808)	(7.0)
Operating income	32.4	787,689	34.7	845,767	(58,078)	(6.9)
Operating income	8.6	209,827	5.1	123,329	86,498	70.1
Other income (expenses):						
Interest and dividend income		4,787		6,262	(1,475)	
Interest expense		(3,314)		(4,570)	1,256	
Foreign exchange gains (losses), net		(2,919)		(6,936)	4,017	
Gains (losses) on equity securities, net		(244)		50,999	(51,243)	
Other, net		4,625		28,723	(24,098)	
Income before income taxes	0.2	2,935	3.0	74,478	(71,543)	(96.1)
Income before income taxes	8.8	212,762	8.1	197,807	14,955	7.6
Income taxes						
Current		43,697		65,565	(21,868)	
Deferred		12,359		(11,130)	23,489	
Income taxes	2.3	56,056	2.2	54,435	1,621	3.0
Equity in net earnings (losses) of affiliated companies	0.0	418	0.0	872	(454)	(52.1)
Net income	6.5	157,124	5.9	144,244	12,880	8.9
Less: Net (income) loss attributable to the noncontrolling interests	(0.8)	(19,018)	(0.1)	(3,550)	(15,468)	435.7
Net income attributable to FUJIFILM Holdings	5.7	138,106	5.8	140,694	(2,588)	(1.8)

Three months ended March 31

Amount Unit: Millions of yen

	Three months ended March 31, 2019 From January 1, 2019 To March 31, 2019		Three months ended March 31, 2018 From January 1, 2018 To March 31, 2018		Change	
	%		%		Amount	%
Revenue:	100.0	631,673	100.0	623,683	7,990	1.3
Cost of sales:	61.5	388,597	61.3	382,475	6,122	1.6
Gross profit	38.5	243,076	38.7	241,208	1,868	0.8
Operating expenses:						
Selling, general and administrative	24.0	151,269	30.7	191,067	(39,798)	(20.8)
Research and development	6.4	40,327	8.0	49,962	(9,635)	(19.3)
	30.4	191,596	38.7	241,029	(49,433)	(20.5)
Operating income	8.1	51,480	0.0	179	51,301	28,659.8
Other income (expenses):						
Interest and dividend income		733		1,532	(799)	
Interest expense		(501)		(856)	355	
Foreign exchange gains (losses), net		(379)		(7,604)	7,225	
Gains (losses) on equity securities, net		5,193		31,689	(26,496)	
Other, net		1,671		(1,672)	3,343	
	1.1	6,717	3.7	23,089	(16,372)	(70.9)
Income before income taxes	9.2	58,197	3.7	23,268	34,929	150.1
Income taxes	2.7	17,208	2.2	13,833	3,375	24.4
Equity in net earnings (losses) of affiliated companies	0.3	1,747	0.2	893	854	95.6
Net income	6.8	42,736	1.7	10,328	32,408	313.8
Less: Net (income) loss attributable to the noncontrolling interests	(0.9)	(5,682)	0.9	5,856	(11,538)	-
Net income attributable to FUJIFILM Holdings	5.9	37,054	2.6	16,184	20,870	129.0

(Consolidated Statements of Comprehensive Income)**Year ended March 31**

Amount Unit: Millions of yen

	Year ended March 31, 2019 From April 1, 2018 To March 31, 2019	Year ended March 31, 2018 From April 1, 2017 To March 31, 2018	Change
Net income	157,124	144,244	12,880
Other comprehensive income (loss), net of tax:			
Unrealized gains (losses) on securities	(2)	(23,723)	23,721
Foreign currency translation adjustments	6,322	(8,031)	14,353
Pension liability adjustments	885	(3,526)	4,411
Unrealized gains (losses) on derivatives	188	569	(381)
Other comprehensive income (loss)	7,393	(34,711)	42,104
Comprehensive income (loss)	164,517	109,533	54,984
Less: Comprehensive (income) loss attributable to noncontrolling interests	(20,245)	(1,902)	(18,343)
Comprehensive income (loss) attributable to FUJIFILM Holdings	144,272	107,631	36,641

Three months ended March 31

Amount Unit: Millions of yen

	Three months ended March 31, 2019 From January 1, 2019 To March 31, 2019	Three months ended March 31, 2018 From January 1, 2018 To March 31, 2018	Change
Net income	42,736	10,328	32,408
Other comprehensive income (loss), net of tax:			
Unrealized gains (losses) on securities	1	(25,261)	25,262
Foreign currency translation adjustments	4,462	(48,255)	52,717
Pension liability adjustments	(2,959)	(7,068)	4,109
Unrealized gains (losses) on derivatives	77	149	(72)
Other comprehensive income (loss)	1,581	(80,435)	82,016
Comprehensive income (loss)	44,317	(70,107)	114,424
Less: Comprehensive (income) loss attributable to noncontrolling interests	(6,910)	11,808	(18,718)
Comprehensive income (loss) attributable to FUJIFILM Holdings	37,407	(58,299)	95,706

(3) Consolidated Statements of Changes in Shareholders' Equity

Amount Unit: Millions of yen

	Common stock	Additional paid-in capital	Retained earnings	Accumulated other comprehensive income (loss)	Treasury stock	FUJIFILM Holdings shareholders' equity	Noncontrolling interest	Total Equity
Balanced at April 1, 2017	40,363	81,761	2,275,626	(54,720)	(299,471)	2,043,559	224,499	2,268,058
Comprehensive income (loss):								
Net income			140,694			140,694	3,550	144,244
Change in net unrealized losses on securities				(23,717)		(23,717)	(6)	(23,723)
Foreign currency translation adjustments				(7,843)		(7,843)	(188)	(8,031)
Pension liability adjustments				(2,038)		(2,038)	(1,488)	(3,526)
Change in net unrealized gains on derivatives				535		535	34	569
Net comprehensive income						107,631	1,902	109,533
Purchases of stock for treasury					(50,024)	(50,024)		(50,024)
Sales of stock from treasury		212			1,780	1,992		1,992
Dividends paid to FUJIFILM Holdings shareholders			(32,527)			(32,527)		(32,527)
Dividends paid to noncontrolling interests							(6,521)	(6,521)
Stock acquisition rights		(330)				(330)		(330)
Equity transactions with non controlling interests and other		(2,490)			11,323	8,833	(308)	8,525
Balanced at March 31, 2018	40,363	79,153	2,383,793	(87,783)	(336,392)	2,079,134	219,572	2,298,706
Cumulative effect of application of Accounting Standards Update 2016-01			18,976	(18,976)				
Cumulative effect of application of Accounting Standards Update 2016-16			296			296	99	395
Comprehensive income (loss):								
Net income			138,106			138,106	19,018	157,124
Change in net unrealized losses on securities				(2)		(2)		(2)
Foreign currency translation adjustments				5,898		5,898	424	6,322
Pension liability adjustments				61		61	824	885
Change in net unrealized gains (losses) on derivatives				209		209	(21)	188
Net comprehensive income						144,272	20,245	164,517
Purchases of stock for treasury					(100,018)	(100,018)		(100,018)
Sales of stock from treasury		(212)	(49)		1,390	1,129		1,129
Dividends paid to FUJIFILM Holdings shareholders			(33,403)			(33,403)		(33,403)
Dividends paid to noncontrolling interests							(7,752)	(7,752)
Stock acquisition rights		(70)				(70)		(70)
Equity transactions with non controlling interests and other		(54,377)				(54,377)	(24,286)	(78,663)
Balanced at March 31, 2019	40,363	24,494	2,507,719	(100,593)	(435,020)	2,036,963	207,878	2,244,841

(4) Consolidated Statements of Cash Flows

Amount Unit: Millions of yen

	Year ended March 31, 2019 From April 1, 2018 To March 31, 2019	Year ended March 31, 2018 From April 1, 2017 To March 31, 2018	Change
Operating activities			
Net income	157,124	144,244	12,880
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	129,932	127,642	2,290
Gain on remeasurement of step acquisitions	-	(20,838)	20,838
(Gains) losses on equity securities	244	(50,999)	51,243
Deferred income taxes	12,359	(11,130)	23,489
Equity in net (gains) losses of affiliated companies, net of dividends received	4,719	1,142	3,577
Changes in operating assets and liabilities:			
Notes and accounts receivable	4,885	41,342	(36,457)
Inventories	(12,287)	(7,518)	(4,769)
Notes and accounts payable - trade	(12,469)	(19,999)	7,530
Accrued income taxes and other liabilities	(80,408)	68,551	(148,959)
Other	45,244	(11,285)	56,529
Subtotal	92,219	116,908	(24,689)
Net cash provided by operating activities	249,343	261,152	(11,809)
Investing activities			
Purchases of property, plant and equipment	(68,549)	(63,043)	(5,506)
Purchases of software	(20,471)	(18,541)	(1,930)
Proceeds from sales and maturities of marketable and investment securities	2,545	73,270	(70,725)
Purchases of marketable and investment securities	(23,349)	(5,063)	(18,286)
(Increase) decrease in time deposits, net	(3,630)	40,691	(44,321)
Increase in investments in and advances to affiliated companies	(10,456)	(3,052)	(7,404)
Acquisitions of businesses, net of cash acquired	(84,310)	(127,269)	42,959
Other	(365)	(8,779)	8,414
Net cash used in investing activities	(208,585)	(111,786)	(96,799)
Financing activities			
Proceeds from long-term debt	100,035	2,100	97,935
Repayments of long-term debt	(25,947)	(165,416)	139,469
Increase (decrease) in short-term debt, net	(8,123)	(7,171)	(952)
Cash dividends paid to shareholders	(33,166)	(31,714)	(1,452)
Subsidiaries' cash dividends paid to noncontrolling interests	(7,752)	(6,521)	(1,231)
Net purchases of stock for treasury	(100,018)	(50,023)	(49,995)
Capital transactions with noncontrolling interests and other	(78,551)	(216)	(78,335)
Net cash used in financing activities	(153,522)	(258,961)	105,439
Effect of exchange rate changes on cash and cash equivalents	(735)	1,883	(2,618)
Net decrease in cash and cash equivalents	(113,499)	(107,712)	(5,787)
Cash and cash equivalents at beginning of year	768,246	875,958	(107,712)
Cash and cash equivalents at end of year	654,747	768,246	(113,499)

(5) Notes to Consolidated Financial Statements**Note Relating to the Going Concern Assumption**

N/A

Summary of Significant Accounting Policies**(A) Scope of consolidated subsidiaries**

Number of Subsidiaries : 279

Main companies : FUJIFILM Corporation, Fuji Xerox Co., Ltd., FUJIFILM Toyama Chemical Co., Ltd.
FUJIFILM Wako Pure Chemical Corporation and others**(B) Scope of affiliated companies**

Number of Affiliates : 32

Main companies : SANRITZ CORPORATION, FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., and others

(C) Significant Accounting Policies

In May 2014, U.S. Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2014 - 09 "Revenue from Contracts with Customers" and subsequently revised a part of it. These standards define a revenue recognition model consisting of five steps to recognize revenues arising from contracts with all customers except for some exceptions. We have applied these standards from the first quarter of the fiscal year ended March 31, 2019 (commenced on April 1, 2018). Upon adoption of these standards, we applied a method that recognizes the cumulative effect of adopting these standards on the effective date of adoption, which is accepted as transitional measures. As a result of identifying performance obligations under contracts with customers, some of sales promotion expenses, etc., which are consideration paid by the Group to customers and were previously accounted for as selling, general and administrative expenses, are deducted from revenue from the first quarter of the consolidated accounting period. As a result, in the consolidated statements of income for the twelve months and the fourth quarter of the current fiscal year, revenue and selling, general and administrative expenses decreased by ¥4,955 million and ¥1,854 million, respectively, compared with those with the previous accounting standards applied. There is no impact on operating profit or net income. In addition, out of the revenue in the twelve months and the fourth quarter of the current fiscal year, those recognized from lease contracts amounted to ¥48,986 million and ¥10,577 million, respectively.

In January 2016, U.S. Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2016-01 "Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities". These standards require that equity investments be measured at fair value and their changes be recognized in profit or loss, with the exception of equity method investments and consolidated investments. We have applied these standards from the first quarter of the fiscal year ended March 31, 2019 (commenced on April 1, 2018). Upon adoption of these standards, we adjusted the unrealized gains of ¥18,976 million (net of tax) related to equity investment, which was recognized as accumulated other comprehensive income, as the cumulative effect on retained earnings at the beginning of the year.

In October 2016, U.S. Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2016-16 "Income Taxes – Intra-Entity Transfers of Assets Other Than Inventory". These standards require the tax effect to be recognized at the time of intra-entity transfers of assets other than inventory. Under the previous accounting standards, tax effects on assets other than inventory were not recognized until the asset was transferred to a third party. These standards require the cumulative effect to be applied by a method of adjusting the retained earnings at the beginning of the first year of adoption. We have applied these standards from the first quarter of the fiscal year ended March 31, 2019 (commenced on April 1, 2018). The adoption of the Accounting Standards Update 2016-16 has no significant impact on our operating results and financial conditions.

In March 2017, U.S. Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2017-07 "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost". These standards require that periodic pension cost and net periodic postretirement benefit cost be classified into the service cost components and other components, and the service cost components be presented in the same item as employee compensation cost, and the other components in non-operating income and expenses. Also, it is not permitted to capitalize components other than service costs. These standards require that provisions to separately present the service cost components and other components be applied retroactively and that provisions allowing capitalization of only service cost components be applied prospectively. We have applied these standards from the first quarter of the fiscal year ended March 31, 2019 (commenced on April 1, 2018). As a result of the adoption of these standards, operating income will decline and non-operating income and expenses will increase during the twelve months and the fourth quarter consolidated accounting period of the fiscal year ended March 31, 2017 and the twelve months and the fourth quarter consolidated accounting period of the fiscal year ended March 31, 2018. The impact amounts are ¥5,919 million, ¥1,492 million, ¥7,350 million and ¥1,913 million, respectively.

Segment Information**1. Year ended March 31****(A) Operating Segment Information****a. Revenue**

Amount Unit: Millions of yen

	Year ended March 31, 2019 From April 1, 2018 To March 31, 2019		Year ended March 31, 2018 From April 1, 2017 To March 31, 2018		Change	
					Amount	%
Revenue:	%		%			
Imaging Solutions:						
External customers	15.9	386,914	15.7	382,961	3,953	1.0
Intersegment		2,160		2,315	(155)	-
Total		389,074		385,276	3,798	1.0
Healthcare & Material Solutions:						
External customers	42.7	1,038,966	41.2	1,002,602	36,364	3.6
Intersegment		1,559		940	619	-
Total		1,040,525		1,003,542	36,983	3.7
Document Solutions:						
External customers	41.4	1,005,609	43.1	1,047,802	(42,193)	(4.0)
Intersegment		9,177		7,824	1,353	-
Total		1,014,786		1,055,626	(40,840)	(3.9)
Eliminations		(12,896)		(11,079)	(1,817)	-
Consolidated total	100.0	2,431,489	100.0	2,433,365	(1,876)	(0.1)

b. Operating income

Amount Unit: Millions of yen

	Year ended March 31, 2019 From April 1, 2018 To March 31, 2019		Year ended March 31, 2018 From April 1, 2017 To March 31, 2018		Change	
					Amount	%
Operating Income:	%		%			
Imaging Solutions	13.1	51,128	14.5	55,787	(4,659)	(8.4)
Healthcare & Material Solutions	9.4	97,579	9.1	91,377	6,202	6.8
Document Solutions	9.5	96,366	0.8	8,414	87,952	1,045.3
Total		245,073		155,578	89,495	57.5
Corporate expenses and eliminations		(35,246)		(32,249)	(2,997)	-
Consolidated total	8.6	209,827	5.1	123,329	86,498	70.1

Notes

1: The major products and services of each operating segment are as follows:

Imaging Solutions: Color films, digital cameras, color paper, services and equipment for photofinishing, instant photo systems and optical devices

Healthcare & Material Solutions: Equipment and materials for medical systems, cosmetics and supplements, pharmaceuticals, contract development and manufacturing organization of biopharmaceuticals, regenerative medicine, fine chemicals, equipment and materials for graphic arts, inks and industrial inkjet printheads, display materials, recording media, electronic materials

Document Solutions: Digital MFPs, publishing systems, document management software and related solutions and services

Total Assets

Amount Unit: Millions of yen

	As of March 31, 2019	As of March 31, 2018	Change	
			Amount	%
Total assets:				
Imaging Solutions	325,337	341,534	(16,197)	(4.7)
Healthcare & Material Solutions	1,709,713	1,725,703	(15,990)	(0.9)
Document Solutions	1,014,304	1,068,350	(54,046)	(5.1)
Subtotal	3,049,354	3,135,587	(86,233)	(2.8)
Eliminations	(4,161)	(4,771)	610	-
Corporate assets	369,499	362,124	7,375	2.0
Consolidated total	3,414,692	3,492,940	(78,248)	(2.2)

Depreciation and amortization, and Capital expenditures

Amount Unit: Millions of yen

	Year ended March 31, 2019 From April 1, 2018 To March 31, 2019	Year ended March 31, 2018 From April 1, 2017 To March 31, 2018	Change	
			Amount	%
Depreciation and amortization:				
Imaging Solutions	14,060	13,254	806	6.1
Healthcare & Material Solutions	63,093	57,503	5,590	9.7
Document Solutions	50,137	54,685	(4,548)	(8.3)
Corporate	2,642	2,200	442	20.1
Consolidated total	129,932	127,642	2,290	1.8
Capital expenditures:				
Imaging Solutions	10,579	9,427	1,152	12.2
Healthcare & Material Solutions	50,523	42,668	7,855	18.4
Document Solutions	11,672	13,848	(2,176)	(15.7)
Corporate	2,598	1,540	1,058	68.7
Consolidated total	75,372	67,483	7,889	11.7

(B) Geographic Information**a. Revenue**

Amount Unit: Millions of yen

	Year ended March 31, 2019 From April 1, 2018 To March 31, 2019		Year ended March 31, 2018 From April 1, 2017 To March 31, 2018		Change	
					Amount	%
Revenue:	%		%			
Japan:						
External customers	48.7	1,184,554	49.0	1,191,810	(7,256)	(0.6)
Intersegment		474,123		476,647	(2,524)	-
Total		1,658,677		1,668,457	(9,780)	(0.6)
The Americas:						
External customers	18.7	455,592	18.5	451,267	4,325	1.0
Intersegment		54,258		49,875	4,383	-
Total		509,850		501,142	8,708	1.7
Europe:						
External customers	10.1	244,880	9.7	235,826	9,054	3.8
Intersegment		18,579		18,981	(402)	-
Total		263,459		254,807	8,652	3.4
Asia and others:						
External customers	22.5	546,463	22.8	554,462	(7,999)	(1.4)
Intersegment		280,016		296,498	(16,482)	-
Total		826,479		850,960	(24,481)	(2.9)
Eliminations		(826,976)		(842,001)	15,025	-
Consolidated total	100.0	2,431,489	100.0	2,433,365	(1,876)	(0.1)

b. Operating income

Amount Unit: Millions of yen

	Year ended March 31, 2019 From April 1, 2018 To March 31, 2019		Year ended March 31, 2018 From April 1, 2017 To March 31, 2018		Change	
					Amount	%
Operating Income (Loss):	%		%			
Japan	6.4	106,780	3.4	57,086	49,694	87.1
The Americas	4.5	22,904	4.4	22,261	643	2.9
Europe	3.5	9,135	4.6	11,825	(2,690)	(22.7)
Asia and others	8.9	73,786	4.2	35,806	37,980	106.1
Eliminations		(2,778)		(3,649)	871	-
Consolidated total	8.6	209,827	5.1	123,329	86,498	70.1

c. Long - lived assets

Amount Unit: Millions of yen

	As of March 31, 2019	As of March 31, 2018	Change	
			Amount	%
Long - lived assets				
Japan	373,513	382,344	(8,831)	(2.3)
The Americas	67,318	55,659	11,659	20.9
Europe	34,772	36,378	(1,606)	(4.4)
Asia and others	51,194	63,164	(11,970)	(19.0)
Consolidated total	526,797	537,545	(10,748)	(2.0)

d. Overseas revenue (Destination Base)

Amount Unit: Millions of yen

	Year ended March 31, 2019 From April 1, 2018 To March 31, 2019		Year ended March 31, 2018 From April 1, 2017 To March 31, 2018		Change	
	Amount	%	Amount	%	Amount	%
Revenue:		%		%		
Domestic	1,006,536	41.4	1,006,512	41.4	24	0.0
Overseas:						
The Americas	463,394	19.1	462,768	19.0	626	0.1
Europe	315,667	13.0	315,251	13.0	416	0.1
Asia and others	645,892	26.5	648,834	26.6	(2,942)	(0.5)
Subtotal	1,424,953	58.6	1,426,853	58.6	(1,900)	(0.1)
Consolidated total	2,431,489	100.0	2,433,365	100.0	(1,876)	(0.1)

Note: The presentation of the overseas revenue (Destination Base) has been classified and disclosed based on the customer's location.

2. Three months ended March 31

(A) Operating Segment Information

Revenue

Amount Unit: Millions of yen

	Three months ended March 31, 2019 From January 1, 2019 To March 31, 2019		Three months ended March 31, 2018 From January 1, 2018 To March 31, 2018		Change	
					Amount	%
Revenue:	%		%			
Imaging Solutions:						
External customers	13.2	83,081	13.7	85,234	(2,153)	(2.5)
Intersegment		537		534	3	-
Total		83,618		85,768	(2,150)	(2.5)
Healthcare & Material Solutions:						
External customers	44.3	280,112	44.0	274,341	5,771	2.1
Intersegment		441		301	140	-
Total		280,553		274,642	5,911	2.2
Document Solutions:						
External customers	42.5	268,480	42.3	264,108	4,372	1.7
Intersegment		2,905		2,160	745	-
Total		271,385		266,268	5,117	1.9
Eliminations		(3,883)		(2,995)	(888)	-
Consolidated total	100.0	631,673	100.0	623,683	7,990	1.3

Note: Major products and services of each operating segment are as follows:

Imaging Solutions	Color films, digital cameras, color paper, services and equipment for photofinishing, instant photo systems and optical devices
Healthcare & Material Solutions	Equipment and materials for medical systems, cosmetics and supplements, pharmaceuticals, contract development and manufacturing organization of biopharmaceuticals, regenerative medicine, fine chemicals, equipment and materials for graphic arts, inks and industrial inkjet printheads, display materials, recording media, electronic materials
Document Solutions	Digital MFPs, publishing systems, document management software and related solutions and services

(B) Geographic Information

Overseas Revenue (Destination Base)

Amount Unit: Millions of yen

	Three months ended March 31, 2019 From January 1, 2019 To March 31, 2019		Three months ended March 31, 2018 From January 1, 2018 To March 31, 2018		Change	
					Amount	%
Revenue:	%		%			
Domestic	44.6	281,876	43.8	273,021	8,855	3.2
Overseas:						
The Americas	17.4	109,695	17.4	108,674	1,021	0.9
Europe	12.4	78,513	13.2	82,116	(3,603)	(4.4)
Asia and others	25.6	161,589	25.6	159,872	1,717	1.1
Subtotal	55.4	349,797	56.2	350,662	(865)	(0.2)
Consolidated total	100.0	631,673	100.0	623,683	7,990	1.3

Amounts Per Share of Common Stock

	Year ended March 31, 2019	Year ended March 31, 2018
	Yen	Yen
FUJIFILM Holdings shareholders' equity per share	4,976.88	4,832.62
Net income attributable to FUJIFILM Holdings per share	326.81	322.62
Net income attributable to FUJIFILM Holdings per share (Assuming full dilution)	325.82	321.55

Subsequent Event

N/A